Introduction {#Sec1}
============

Adaptations in maternal calcium homeostasis and balance occur during late pregnancy and lactation to meet requirements for foetal bone mineralisation and calcium secretion into breast milk. In Western women, intestinal calcium absorption increases in pregnancy \[[@CR1]--[@CR3]\]. Little change in the maternal bone mineral status (bone mineral density or content) is observed, although an increase in bone remodelling is reported \[[@CR3], [@CR4]\]. During lactation, bone resorption and renal calcium conservation are increased in both Western and Gambian women with concomitant decreases in bone mineral status \[[@CR1], [@CR5]--[@CR7]\]. Changes in maternal bone mineral status and bone resorption during pregnancy and lactation appear to be independent of calcium intake in populations with a wide range of habitual calcium intakes \[[@CR3], [@CR4]\].

Uncertainty exists about how maternal calcium metabolism and balance are regulated, particularly in women with very low calcium intakes. During pregnancy and early lactation, plasma PTH concentration (pPTH) is suppressed, but plasma 1,25-dihydroxyvitamin D (p1,25(OH)~2~D) is similar or elevated compared to non-pregnant, non-lactating women (NPNL) \[[@CR3], [@CR8], [@CR9]\]. This may be explained partly by the increase in the plasma concentration of PTH-related peptide (PTHrP). The role of PTHrP in the regulation of maternal calcium and bone metabolism is unclear, however, as it does not appear to respond to changes in plasma calcium \[[@CR2], [@CR4], [@CR10]\], unlike PTH which remains responsive to changes in calcium metabolism during pregnancy and lactation despite its lower concentration \[[@CR1], [@CR11]\]. Earlier studies in Australia and USA applied calcium-loading (or oral calcium-tolerance) tests to investigate changes in calcium homeostasis in pregnant and lactating women with calcium intakes close to recommendations \[[@CR1], [@CR2]\]. The calcium-loading test utilizes a single oral dose of calcium and is designed to test the response of the calciotropic hormones and calcium handling in the intestine and kidney to provide a proxy measure of the rate of calcium absorption and renal calcium excretion \[[@CR2], [@CR12]\]. In this pilot study, we investigated the calcemic and calciuric responses to oral calcium loading in pregnant, lactating and NPNL rural Gambian women with a habitual calcium intake of \~350 mg/day. We aimed to provide pilot data to investigate adaptations in calcium homeostasis during the reproductive cycle in Gambian women and to investigate that there was an indication of the pattern of response to be different from women with a higher calcium intake in order to consider whether a larger study is warranted.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

Healthy pregnant, lactating and non-pregnant, non-lactating (NPNL) women, ten in each group, were identified through the West Kiang database and were recruited in 2008 from the villages of Keneba, Manduar and Kanton Kunda, in West Kiang, The Gambia, West Africa. Subjects were matched for age and parity at inclusion. Trained fieldworkers explained the study in the participant's native language, and an informed written consent was obtained. Pregnant women were 30--36 weeks gestation, based on predicted date of delivery as estimated by a midwife after an ultrasound scan and the date of the last menstrual period, and was back tracked on the basis of the date of birth of the baby. Lactating women were 2--4 months post-partum based on the date of birth of their child and were demand breastfeeding. NPNL women reported to have recently had their menstrual period and were at least 3 months post-lactation; the period of breastfeeding in this region is typically 18--24 months \[[@CR7]\]. We did not collect information on the use of contraceptives as this is a sensitive issue in this community and would have been unlikely to result in accurate data. The study took place at the MRC Keneba Fieldstation in the wet season (June--September). The study was approved by the joint Gambian Government/MRC Ethics Committee, and the London School of Hygiene and Tropical Medicine Ethics Committee.

Calcium-loading test {#Sec4}
--------------------

The strictly standardized protocol was based on that used in pregnant, lactating and NPNL white Australian women by Kent et al. \[[@CR1]\]. Women arrived between 0700 and 0800 hours after an overnight fast and were asked to empty their bladder 60 min prior to being given the calcium dose. This consisted of 1 g elemental calcium (given as two CaCO~3~ tablets; Calcichew, Shire Pharmaceuticals Ltd., UK). Water (200 ml) was given every hour. Blood samples were taken 30 min before (pre-Ca) and 180 min after the calcium (post-Ca) dose. All urine produced between 60 min pre-Ca and baseline and from baseline to 120 and 240 min post-Ca was collected. All samples were collected within 5 min before or after the scheduled time). A small standardized meal (300 g of porridge, composed of 49 g millet flour, 230 ml water, 1 g salt, 20 g sugar; composition: 780 kJ, 14 mg calcium, 36 mg phosphorus, 0.1 mg phytates) was given 30 min post-Ca, and participants were requested to eat it all.

Sample collections and laboratory analyses {#Sec5}
------------------------------------------

Blood samples were collected into pre-cooled lithium--heparin (LH) or EDTA tubes (S-Monovette, Sarstedt Ltd, Leicester, UK). The EDTA sample was placed on ice immediately. The LH whole blood sample was measured for ionized calcium (iCa; pH 7.4 corrected values), haemoglobin (Hb) and pH within 10 min of collection (ABL77 blood gas analyser, Radiometer, Brønshøj, Denmark), and the remaining sample was then placed on ice. Plasma was separated within 1 h of collection in a refrigerated centrifuge at 1,800 g for 20 min, and aliquots were stored at −70 °C.

Urine was collected in acid-washed containers, mixed thoroughly. Non-acidified and acidified (concentrated hydrochloric acid (HCl), 10 ml/l, laboratory reagent grade, SG 1.18, Fisher Scientific) aliquots were taken and stored at −20 °C.

After completion of the study, plasma and urine samples were packed and shipped on dry ice to MRC Human Nutrition Research, Cambridge and subsequently stored at −80 °C until analysis.

LH plasma was used for the measurement of 1,25(OH)~2~D (radioimmunoassay IDS Ltd., Tyne and Wear, UK), 25-hydroxyvitamin D (25(OH)D), bone-specific alkaline phosphatase (BALP), osteocalcin (OC) (all chemiluminescent immunometric automated assays, CLIA; DiaSorin, Stillwater, MN, USA), β C-terminal cross-linked telopeptide of type 1 collagen (βCTX) (ELISA, IDS Ltd., Tyne & Wear, UK), cAMP (ELISA, R&D Systems, Abington, UK), total calcium (tCa), phosphate (P), creatinine (Cr) and albumin (Alb) (colorimetric methods, Kone Lab 20i clinical chemistry analyser platform, Kone Espoo, Finland). EDTA plasma was used for the measurement of PTH by immunoassay (Immulite, Siemens Healthcare Diagnostics Ltd, Camberley, UK).

Urinary (u) calcium (uCa), phosphate (uP) and creatinine (uCr) were measured in acidified urine (colorimetric methods, Kone Lab 20i, as above). Concentrations of uCa and uP were expressed as a ratio relative to uCr to adjust for urinary volume. Urinary cAMP was measured in non-acidified urine (ELISA, R&D Systems, as above).

All assays except PTH (between-assay coefficient of variation (CV), 4.7 %) were performed in duplicate. Assay performance was monitored using kit and in-house controls and under strict standardisation according to ISO 9001:2000. Quality assurance of 25(OH)D and 1,25(OH)~2~D assays were performed as part of the Vitamin D External Quality Assessment Scheme ([www.deqas.org](http://www.deqas.org/)) and PTH assays as part of the National External Quality Assessment Scheme ([www.ukneqas.org.uk](http://www.ukneqas.org.uk/)), and all were within accepted limits.

Within- and between-assay CVs for 1,25(OH)~2~D were 7.5 and 9.0 %. Cross-reactivity of the assay is 100 and 91 % for 1,25(OH)~2~D~3~ and 1,25(OH)~2~D~2~, respectively. Cross-reactivity of the 25(OH)D assay is 100 and 104 % for 25(OH)D~3~ and 25(OH)D~2~, respectively. Within- and between-assay CVs were 3.7 and 2.9, 1.6 and 3.6, and 3.8 and 4.0 % for 25(OH)D, BALP and OC, respectively. The within- and between-assay CVs for βCTX were 2.9 and 1.4 %. Within- and between-assay CVs for all Kone assays were \<2 and \<4 %, respectively. Within- and between-assay CVs for pcAMP and ucAMP were 6.0 and 4.8 %.

Statistics, data handling and derived variables {#Sec6}
-----------------------------------------------

Data processing and statistics were performed using Microsoft Excel 2010 (Microsoft Corp., Seattle, WA, USA) and Linear Model Software in Data Desk 6.0 (Data Description, Inc., Ithaca, NY, USA). Non-normally distributed data were transformed to natural logs. Within- and between-group differences were analysed with ANOVA or ANCOVA as appropriate, with Scheffé post-hoc tests. The absolute change in each analyte was examined to investigate the response to calcium loading. The level of significance was set at *P* ≤ 0.05. Because of the small numbers of participants, *P* values ≤0.10 are also reported to indicate possible trends in the data.

The following variables were derived:Albumin-corrected calcium (pCaAlb =ptCa + \[(40 − Alb (g/L))×0.02\]) \[[@CR13], [@CR14]\].The fractional excretion of calcium (Ca~e~ = (uCa/uCr)×pCr) and of P (P~e~ = (uP/uCr)×pCr) \[[@CR2]\].Nephrogenic cAMP (NcAMP = (ucAMP − pcAMP) × (pCr/uCr)) \[[@CR14]\]The renal calcium threshold (TmCa/GFR = \[(0.56 × pCa) − Ca~e~\]/\[1 − 0.08log~e~(0.56 × pCa)/Ca~e~)\]).The renal threshold for phosphate (TmP/GFR) = TRP×pP, if TRP ≤ 0.86. If TRP \> 0.86, TmP/GFR = *α* × pP. TRP = 1 -- \[(uP/pP) × (pCr/uCr)\] and *α* = 0.3 × TRP/\[1 -- (0.8 × TRP)\] as described by Payne \[[@CR15]\].

For the calculation of albumin-corrected calcium, different equations \[[@CR13], [@CR16], [@CR17]\] and group-specific equations, as based on regression analyses, were used because the albumin--calcium relationships may differ between populations and reproductive stages. Bland--Altman analyses \[[@CR18]\] showed no significant differences between the values calculated according to different methods. Further, regression analyses of the calcium--albumin relationship showed no significant group interaction (*P* = 0.4). Therefore, the Payne equation \[[@CR13], [@CR16]\] was used for further analyses. The dataset contained one outlier in Ca~e~ in the pregnant group as detected by standard procedures (Data Desk 6.0), and this value was excluded from analyses, but its inclusion made no material difference to the conclusions drawn.

We aimed to be able to detect a difference of 1.5 SD between groups with a sample size of *n* = 10 per group. A formal power calculation could not be performed for this study as the mean and distribution of most of the measured biochemical parameters are known to be markedly different from those in Western populations, and no data for the response to calcium loading are available in this population.

Results {#Sec7}
=======

Subject characteristics and baseline data {#Sec8}
-----------------------------------------

Subject characteristics are given in Table [1](#Tab1){ref-type="table"}. Age, height, parity and weight were not significantly different between groups. Concentrations of pAlb, pCr, Hb and ptCa were significantly lower in pregnant women than in lactating and NPNL women. There were no significant group differences in ptCa when corrected for pAlb, or in p25(OH)D, iCa, pP, uCa/Cr, uP/Cr, TmCa/GFR, TmP/GFR, Ca~e~ and P~e~ (Table [1](#Tab1){ref-type="table"}; Figs. [1](#Fig1){ref-type="fig"}--[3](#Fig3){ref-type="fig"}). The p1,25(OH)~2~D concentration was significantly higher and pOC and BALP (tendency) lower in pregnant than in lactating and NPNL women. In pregnant women, pPTH was lower compared to lactating women, and NcAMP was higher than in NPNL women. In lactating women, pPTH, p1,25(OH)~2~D and pβCTX concentrations were or tended to be (*P* ≤ 0.1) higher than in NPNL women (Table [1](#Tab1){ref-type="table"}; Figs. [1](#Fig1){ref-type="fig"}--[3](#Fig3){ref-type="fig"}).Table 1Subject characteristics and baseline values of markers of calcium, phosphate and bone metabolismPregnantLactatingNon-pregnant, non-lactating*n* = 10*n* = 10*n* = 10Subject characteristicsAge (years)29.7 ± 2.227.3 ± 2.027.6 ± 2.2Weight (kg)62.5 ± 3.659.4 ± 2.855.8 ± 2.4Height (m)1.62 ± 0.021.65 ± 0.011.59 ± 0.02Parity4.6 ± 0.8 (1--8)^1^3.6 ± 0.78 (1--7)^1^3.0 ± 0.9 (0--7)^1^Gestation/post-partum (weeks)32.6 ± 0.514.2 ± 0.20−pCr(mmol/L)59.2 ± 1.5^NL^70.3 ± 2.974.0 ± 2.5pAlb (g/L)25.5 ± 0.8^NL^36.7 ± 0.9134.1 ± 0.65Hb (g/L)11.2 ± 0.38^NL^13.2 ± 0.5713.0 ± 0.35p25(OH)D (nmol/L)59.7 ± 3.863.2 ± 5.170.4 ± 4.6Markers of renal mineral handlingTmCa/GFR (mmol/L GFR)2.31 ± 0.202.39 ± 0.152.15 ± 0.15TmP/GFR (mmol/L GFR)1.25 ± 0.061.42 ± 0.081.18 ± 0.09Values are given as mean ± SE or when indicated^1^ as range (min--max)*Cr* creatinine, *Hb* haemoglobin, *25(OH)D* 25(OH) vitamin D, *p* plasma, *TmCa/GFR* the renal calcium threshold, *TmP/GFR* the renal threshold for phosphateLetters are used to indicate significant between-group differences in baseline values as tested by ANOVA/Scheffé (*P* ≤ 0.05); *N* significantly different to non-pregnant and non-lactating women; *L* significantly different to lactating womenFig. 1Baseline (*black*) and response (*grey*) of total plasma calcium (Ca; **a**), ionized Ca (**b**), phosphate (P; **c**), parathyroid hormone (PTH; **d**), nephrogenic cAMP (NcAMP; **e**) and 1,25-dihydroxy vitamin D (1,25(OH)~2~D; **f**) to calcium loading in pregnant, lactating and non-pregnant and non-lactating women. Data are presented as mean + SE. *Asterisk* is used to indicate significant within-group differences compared to baseline as tested with paired *t* tests. *Letters* are used to indicate significant between-group differences in baseline values as tested by ANOVA/Scheffé (*P* ≤ 0.05); *N* significantly different to non-pregnant and non-lactating women; *L* significantly different to lactating women. *Circumflex accent* tendency to be significantly different as tested by ANOVA/Scheffé (*P* ≤ 0.10); No significant between-group differences in the change of any of these analytes were found

There was a consistent pattern of uCa/Cr, Ca~e~ and P~e~ to be lower in pregnant and lactating than in NPNL and of pP, uP/Cr and TmP/GFR to be higher in pregnant women, although this did not reach statistical significance.

Post-Ca loading {#Sec9}
---------------

Concentrations of iCa and ptCa significantly increased and pPTH, NcAMP and pβCTX decreased in all groups (Figs. [1](#Fig1){ref-type="fig"}--[3](#Fig3){ref-type="fig"}). Only in pregnant women was there a significant decrease in pP and an increase in p1,25(OH)~2~D. In lactating women, pOC decreased. No differences were found in the plasma concentration of BAP possibly due to its long half-life. In all groups, uCa/Cr significantly increased and uP/Cr decreased from 120 to 240 min post-loading. This was paralleled by a significant increase in TmP/GFR and decrease in P~e~ in all groups. TmCa/GFR decreased and Ca~e~ increased only in pregnant women. The magnitude of change did not differ significantly between groups for any of the analytes in blood and urine.

Relationships between the increases in ptCaAlb and in Ca~e~ and pP and P~e~ are shown in Fig. [2c, d](#Fig2){ref-type="fig"}. Significant increases in Ca~e~ per unit of ptCaAlb were found in pregnant women only. Significant decreases in P~e~ per unit of pP were found in all groups.Fig. 2Response in renal excretion of calcium (urine Ca; **a**) and phosphate (urine P; **b**) expressed as a ratio to urinary creatinine (Cr) to Ca loading in pregnant, lactating and non-pregnant and non-lactating women. Relationships between the response in albumin-corrected plasma calcium (ptCaAlb) and fractional Ca excretion (Ca~e~) and plasma P (pP) and fractional P excretion (P~e~) are shown in **c** and **d**. *Symbols* are used to indicate pregnant (*black square*), lactating (*black triangle*) and non-pregnant and non-lactating women (*black diamond*). *Asterisk* is used to indicate significant within-group differences compared to baseline (pre-Ca) and *cross* compared to 120 min post-Ca as tested with paired t-tests. Data are presented in mean + SE. No significant between-group differences in the change of any of these analytes were found. Further explanations of symbols and abbreviations used are described in Fig. [1](#Fig1){ref-type="fig"}Fig. 3Response of plasma markers of bone resorption (beta C-terminal cross-linked telopeptide of type 1 collagen (pβCTX; **a**) and formation (bone-specific alkaline phosphatase (BALP; **b**) and osteocalcin (OC; **c**)) to calcium loading in pregnant, lactating and non-pregnant and non-lactating women. Data are presented as mean + SE. No significant between-group differences in the change of any of these analytes were found. See Fig. [1](#Fig1){ref-type="fig"} for further explanation of symbols used

Discussion {#Sec10}
==========

This pilot study showed that in pregnant Gambian women with a low calcium intake, NcAMP and p1,25(OH)~2~D were higher, and bone formation was lower than in NPNL women. There was no evidence for pregnancy-induced absorptive hypercalciuria. In lactating women, pPTH and bone resorption were higher and p1,25(OH)~2~D tended to be higher. Pregnant, lactating and NPNL women responded in a similar way and to a similar extent to calcium loading. This may indicate that pregnant, lactating and NPNL women from The Gambia may have similar rates of intestinal calcium absorption and extent of renal calcium conservation. The physiological changes in calcium and bone metabolism occurring in pregnancy and lactation may not lead to increases in calcium conservation.

These findings differ from those reported in pregnant and lactating women with calcium intakes close to Western recommendations \[[@CR1], [@CR2]\]. Those studies showed a greater response in ptCa, iCa and urinary calcium excretion in pregnant women, whereas lactating women showed a lower post-loading calcium excretion. These responses are indicative of an up-regulation of intestinal calcium absorption and renal reabsorption of calcium, respectively \[[@CR2], [@CR12]\]. However, further studies specifically designed to assess calcium economy in the intestine and kidney are needed to confirm these findings.

The differences in the response to calcium loading and results of our previous studies of pregnant and lactating women from The Gambia may indicate that the adaptations in calcium homeostasis may be different for Western and Gambian women. On theoretical grounds and as shown in our earlier studies in this population \[[@CR19]\], it may be expected that with a calcium intake of \~350 mg/day, calcium absorption and renal calcium reabsorption are near their physiological maximum to meet the requirements for obligatory calcium losses in urine and faeces and, additionally during the reproductive cycle, for foetal skeletal mineralisation, secretion into breast milk (\~200--300 mg/day) and post-lactational maternal bone mineral accretion \[[@CR3]\]. This is underpinned by the low urinary calcium losses in Gambian NPNL and pregnant women shown in this study and other studies in this population \[[@CR7]\], and by the absence of or only a moderate decrease in, urinary calcium losses during lactation as measured in 24 h, fasting and post-loading urine collections (this study; \[[@CR7]\]).

An alternative explanation for the absence of differences in the calcemic response between reproductive stages is the length of lactation (up to 2 years) and the typically short interval between cessation of lactation and next conception in this population \[[@CR7]\]. The NPNL women in this study may therefore be in a different physiological state than those women included in other reports \[[@CR1], [@CR2]\] and may have a greater or more prolonged rate of calcium incorporation into the maternal skeleton in response to cessation of lactation. The three groups were matched for age and parity, and the NPNL women were eumenhorreic. It is, therefore, unlikely that the findings of the study reflect biological differences in the ability to conceive.

Despite the apparent moderate differences in calcium homeostasis between pregnant and lactating Gambian women compared to the differences seen in Western women, our earlier studies have shown that the changes in bone mineral status in lactating Gambian mothers at 13 weeks post-partum are similar to those reported for breastfeeding mothers with higher calcium intakes \[[@CR5], [@CR7]\]. This is consistent with other findings that dietary calcium intake is not a predictor of the changes in maternal bone mineral status associated with lactation \[[@CR3], [@CR4]\]. The conservation of bone mineral may be partly explained by the lower calcium outputs in breast milk, as mean milk calcium concentrations from Gambian women are lower than those of British women \[[@CR7], [@CR20], [@CR21]\]. Together with a high degree of renal calcium conservation during both pregnancy and lactation, a decrease in bone formation during pregnancy and an increase in bone resorption during lactation \[[@CR5], [@CR7]\], these adaptations may be sufficient to meet the calcium requirements for foetal skeletal mineralisation and transfer in breast milk amongst Gambian women.

In all groups, plasma PTH was relatively high. This is a common finding in this population and is likely to be due to their low calcium and high phytate intake \[[@CR7], [@CR17], [@CR22]\]. In parallel to findings in Western women, NcAMP was relatively high for its concurrent plasma PTH concentration in pregnant Gambian women, but both did respond significantly to an acute calcium load. This suggests that, as in Western women, the parathyroid gland in Gambian women adapted to a low calcium intake is responsive to change in plasma calcium, but that other regulatory factors such as PTHrP are involved in calcium and phosphate metabolism during pregnancy.

There are several limitations of this study. Firstly, it included only ten women per group, and calcium-loading tests were performed on a cross-sectional basis. This will have limited the power of the statistical analyses and conclusions about changes that might be expected within individuals. In addition, during pregnancy, expansion of the plasma volume may have confounded the observed response particularly of plasma calcium in this and previous studies. This may only partly be corrected for by the use of ptCaAlb.

Comparability to the work by Gertner et al. \[[@CR2]\] and Kent et al. \[[@CR1]\] may be limited due to small differences between protocols. Gertner et al. \[[@CR2]\] investigated women after 1 week on a standardized diet of 800 mg calcium per day. In addition, in the studies performed by Kent et al. \[[@CR1]\] and Gertner et al. \[[@CR2]\], no breakfast was reported as given during the course of the calcium-tolerance test. The breakfast given in this study, although small and low in fat, protein, phytate, calcium and phosphorus content, may have influenced the post-loading response due to a delay in gastric emptying.

In conclusion, there were differences in pPTH, NcAMP and p1,25(OH)~2~D and bone markers between pregnant, lactating and NPNL Gambian women adapted to a low calcium intake similar to those described in Western women. There was no evidence of pregnancy-induced absorptive hypercalciuria as observed in Western women with higher calcium intakes. The response to calcium loading indicates that there may be no differences in renal and intestinal calcium economy between pregnant, lactating and non-pregnant, non-lactating women, potentially due to a high degree of calcium conservation associated with low intakes. Larger studies designed to assess calcium economy in the intestine and kidney are required to confirm these findings.
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